Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

• Market Cap: €219.00M
• Dividend Yield: 1.48%
• Average Volume (3M): 32.76K
• Price to Earnings (P/E): 24.1
• Beta (1Y): 0.29
• Revenue Growth: 5.31%
• EPS Growth: 158.17%
• Country: IT
• Employees: 779
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): N/A
• Shares Outstanding: 22,060,125
• 10 Day Avg. Volume: 35,964
• 30 Day Avg. Volume: 32,755
• PEG Ratio: -0.07
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 0.79
• P/FCF Ratio: 17.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €13.33
• Price Target Upside: 49.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: €9.50 ▲(6.74% Upside)
• Action: Reiterated Date: 12/11/25
• Date: Action: Reiterated 12/11/25

Fine Foods & Pharmaceuticals N.T.M. SpA's stock score is driven by strong technical indicators and solid financial performance, despite challenges in cash flow management. The valuation is moderate, suggesting potential for growth if financial improvements continue.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for the company's products and effective market strategies, supporting long-term business expansion.

Leverage Management

Improved leverage management enhances financial stability and reduces risk, allowing for more flexibility in future investments and operations.

Profit Margin Improvement

Enhanced profit margins reflect operational efficiency and cost control, which can lead to sustained profitability and competitive advantage.

Negative Factors

Cash Flow Challenges

Challenges in free cash flow generation can limit the company's ability to invest in growth opportunities and meet financial obligations, impacting long-term liquidity.

Free Cash Flow Conversion

Negative free cash flow conversion indicates inefficiencies in turning profits into cash, which may hinder the company's ability to fund operations and growth.

Equity Financing

A moderate equity financing level may limit financial resilience, suggesting the need for strengthened equity to support future growth and stability.

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company Description

Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of oral solid forms for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders and granules, capsules, tablets, film-coated tablets, effervescent granules, and hard gelatine capsules. The company also provides nutraceutical products comprising soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatin capsules for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company manufactures and trades in cosmetics products consisting of hair care, skin care, liquid detergents for personal hygiene, skin care emulsions, oral hygiene, deodorants, alcohol-based perfumery, bath and shower gel, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, and liquid soaps; medical surgical aids and medical devices; antiseptics for undamaged skin, hand gel, pre-injection, hydroalcoholic surfaces, and iodine; and orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. The company was founded in 1984 and is headquartered in Verdellino, Italy.

How the Company Makes Money

Fine Foods & Pharmaceuticals N.T.M. SpA generates revenue primarily through the sale of its core products, including food ingredients and pharmaceutical excipients. The company employs a multi-channel distribution model, supplying its products to manufacturers in the food and pharmaceutical industries. Key revenue streams include direct sales to businesses, partnerships with distributors, and collaborations with research institutions for the development of new products. Additionally, FF may benefit from contracts with large-scale clients and participation in international markets, which contribute to its earnings. Strategic partnerships with other companies in the supply chain also enhance its market reach and profitability.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary

Fine Foods & Pharmaceuticals N.T.M. SpA shows positive revenue growth and profitability trends, with improved leverage and equity utilization. However, cash flow management is a concern, particularly in free cash flow generation, which needs improvement for better financial stability.

Income Statement

Fine Foods & Pharmaceuticals N.T.M. SpA has demonstrated a solid revenue growth rate of 2.72% in the TTM, with improving gross and net profit margins compared to previous years. The company has managed to turn around from a negative net profit margin in 2022 to a positive one in the TTM. However, the EBIT and EBITDA margins, while improved, still indicate room for further profitability enhancements.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, indicating better leverage management, with a current ratio of 0.54 in the TTM. Return on equity has also improved to 9.29%, reflecting better utilization of equity. However, the equity ratio suggests a moderate level of equity financing, which could be strengthened further.

Cash Flow

The cash flow analysis shows a decline in free cash flow growth, with a significant negative growth rate in the TTM. The operating cash flow to net income ratio is stable, but the free cash flow to net income ratio is negative, indicating challenges in converting net income into free cash flow. This area requires attention to improve liquidity and cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	256.43M	243.75M	251.81M	206.85M	194.42M	173.03M
Gross Profit	113.06M	80.13M	68.56M	53.63M	55.89M	49.23M
EBITDA	35.49M	30.90M	19.29M	3.64M	9.86M	28.80M
Net Income	12.52M	8.16M	-3.52M	-9.50M	-1.43M	13.36M
Balance Sheet
Total Assets	261.73M	242.59M	241.56M	299.82M	302.81M	207.44M
Cash, Cash Equivalents and Short-Term Investments	17.40M	19.21M	19.15M	76.74M	95.09M	74.95M
Total Debt	67.46M	54.53M	66.39M	120.36M	110.76M	21.19M
Total Liabilities	123.98M	110.53M	114.61M	166.53M	155.59M	66.43M
Stockholders Equity	137.75M	132.06M	126.95M	133.29M	147.22M	141.01M
Cash Flow
Free Cash Flow	306.45K	11.12M	-329.75K	-12.30M	-21.75M	14.66M
Operating Cash Flow	38.85M	45.85M	18.54M	3.69M	-5.83M	30.47M
Investing Cash Flow	-35.82M	-31.56M	45.89M	-15.31M	-36.35M	-12.34M
Financing Cash Flow	5.31M	-14.08M	-55.66M	4.74M	55.95M	-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Negative. The current price of 8.9 is below the 20-day moving average (MA) of 11.09, below the 50-day MA of 10.47, and below the 200-day MA of 9.14, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 29.49 is Positive, neither overbought nor oversold. The STOCH value of 3.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FF	73 Outperform	€219.00M	24.11	―	1.48%	5.31%	158.17%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
VLS	61 Neutral	€112.69M	14.76	9.28%	3.53%	2.66%	9.72%